RAD17 and neoplasm: Clinically, the low expression of the BRCA1/RAD17 signature in HNSCC tumor samples was found to be significantly anti-correlated with miR-205-5p expression (Table S3, Supplementary Materials) and associated with high recurrence (Figure 6D).